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From Same but Different to the Doctrine of Substantial 
Equivalence
John Paull1
A  same-but-different  dichotomy  has  recently  been  encapsulated  within  the  ill-defined 
concept of  “substantial equivalence”. By invoking this concept the  genetically modified 
organism (GMO)  industry  has escaped the  rigors  of  safety testing that might otherwise 
apply. 
The curious concept of “substantial equivalence” grants a presumption of  safety to GMO 
food. This presumption has yet to be earned, and has been used to constrain labelling of 
both GMO and non-GMO food. It is an idea that well serves corporatism. It enables the 
claim  of  difference  to  secure  patent protection, while  upholding  the  contrary  claim  of 
sameness  to  avoid  labelling  and  safety  scrutiny. It  offers  the  best  of  both  worlds  for 
corporate food entrepreneurs, and delivers the worst of both worlds to consumers.
The term “substantial equivalence” has established its currency within the GMO discourse. 
As the opportunities for patenting food technologies expand, the GMO recruitment of  this 
concept will likely be  a dress rehearsal for  the developing debates on the  labelling and 
testing of other techno-foods - including nano-foods and clone-foods.
“Substantial equivalence”
“Are the Seven Commandments the same as they used to be, Benjamin?” asks Clover in 
George Orwell’s “Animal Farm”. By way of response, Benjamin “read out to her what was 
written on the  wall. There was nothing there now except a  single Commandment. It ran: 
ALL ANIMALS ARE  EQUAL  BUT SOME  ANIMALS ARE  MORE  EQUAL THAN 
OTHERS”. After  this reductionist revelation, further novel and curious events at Manor 
Farm, “did not seem strange” (Orwell, 1945, ch. X). 
Equality is a concept at the  very core  of  mathematics; but beyond the domain of  logic, 
equality becomes a  hotly  contested notion - and the domain of  food is no exception. A 
novel food has a regulatory advantage if it can claim to be the same as an established food - 
a food that has proven its worth over centuries, perhaps even millennia - and thus does not 
trigger  new,  perhaps  costly  and  onerous,  testing,  compliance,  and  even  new  and 
burdensome regulations. On the other hand, such a novel food has an intellectual property 
(IP) advantage only in terms of  its difference. And thus there is an entrenched dissonance 
for newly technologised foods, between claiming sameness, and claiming difference.
The same/different dilemma is erased, so some would have it, by appeal to the curious new 
dualist doctrine of  “substantial equivalence” whereby sameness and difference are claimed 
simultaneously,  thereby  creating  a  win/win  for  corporatism,  and  a  loss/loss  for 
consumerism.
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Canberra, ACT 0200, Australia  <john.paull[a]anu.edu.au>This ground has been pioneered, and to some extent conquered, by the GMO industry. The 
conquest has ramifications for other cryptic food technologies, that is technologies that are 
invisible to the consumer and that are not evident to the consumer other than via labelling. 
Cryptic technologies pertaining to  food  include GMOs, pesticides, hormone  treatments, 
irradiation  and,  most  recently,  manufactured  nano-particles  introduced  into  the  food 
production and delivery stream.
Genetic modification of plants was reported as early as 1984 by Horsch et al. The case of 
Diamond v. Chakrabarty resulted in a  US Supreme Court decision that upheld  the  prior 
decision of the US Court of Customs and Patent Appeal that “the fact that micro-organisms 
are alive is without legal significance for purposes of  the  patent law”, and ruled that the 
“respondent’s micro-organism plainly qualifies as patentable subject matter”. This was a 
majority decision of  nine judges, with four judges dissenting (Burger, 1980). It was this 
Chakrabarty  judgement  that has seriously  opened  the  Pandora’s  box of  GMOs  because 
patenting rights makes GMOs an  attractive  corporate  proposition by offering potentially 
unique monopoly rights over food.
The  rear  guard  action against GMOs has  most  often  focussed  on  health  repercussions 
(Smith, 2007), food security issues, and also the potential for corporate malfeasance to hide 
behind  a cloak of  secrecy citing commercial confidentiality (Smith, 2004). Others have 
tilted at the  foundational plank  on  which  the  economics of  the  GMO  industry  sits: “I 
suggest that the main concern is that we do not want a single molecule of  anything we eat 
to  contribute  to,  or  be  patented  and  owned  by,  a  reckless,  ruthless  chemical 
organisation” (Grist, 2008, 22).
The  GMO  industry  exhibits  bipolar  behaviour,  invoking  the  concept  of  “substantial 
difference”  to  claim  patent  rights by  way of  “novelty”, and then claiming  “substantial 
equivalence”  when  dealing  with  other  regulatory  authorities  including  food, drug  and 
pesticide agencies; a case of “having their cake and eating it too” (Engdahl, 2007, 8). This 
is a clever slight-of-rhetoric, laying claim to the best of both worlds for corporations, and 
the worst of  both  worlds for consumers. Corporations achieve  patent protection  and no 
concomitant  specific  regulatory  oversight;  while  consumers  pay  the  cost  of  patent 
monopolization, and are  not necessarily apprised, by way of  labelling or otherwise, that 
they are purchasing and eating GMOs, and thereby financing the GMO industry.
The lemma of  “substantial equivalence” does not bear close scrutiny. It is a fuzzy concept 
that lacks a tight testable definition. It is exactly this fuzziness that allows lots of  wriggle 
room to keep GMOs out of rigorous testing regimes. Millstone et al. (1999, 526) argue that 
“Substantial  equivalence  is a  pseudo-scientific  concept because  it  is  a  commercial  and 
political  judgement  masquerading  as  if  it  is  scientific. It is  moreover, inherently  anti-
scientific  because  it  was  created  primarily  to  provide  an  excuse  for  not  requiring 
biochemical or toxicological tests. It therefore serves to discourage and inhibit informative 
scientific  research”.  “Substantial  equivalence”  grants  GMOs  the  benefit  of  the  doubt 
regarding  safety, and thereby  leaves unexamined the  ramifications for  human consumer 
health, for farm labourer and food-processor health, for the welfare of  farm animals fed a 
diet of  GMO grain, and for  the  well-being of  the  ecosystem, both in general and in its 
particularities.
“Substantial equivalence”  was introduced into the food discourse by an Organisation for 
Economic  Co-operation  and  Development (OECD, 1993)  report: “Safety  Evaluation  of 
Foods  Derived  by  Modern  Biotechnology:  Concepts  and  Principles”.  It  is  from  this 
document  that  the  ongoing  mantra  of  assumed  safety  of  GMOs  derives:  “Modern 
biotechnology  …  does  not  inherently  lead  to  foods  that  are  less  safe  …  Therefore 
evaluation  of  foods  and  food  components  obtained  from organisms  developed  by  the 
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established principles, nor does it require a different standard of safety” (OECD, 1993, 10). 
This was at the time, and remains, an act of  faith, a pro-corporatist and a postcautionary 
approach.  The  OECD  motto  reveals  where  their  priorities  lay:  “For  a  better  world 
economy” (OECD, 2008). The term “substantial equivalence” was preceded by the 1992 
USFDA concept of  “substantial similarity”  (Levidow, Murphy and Carr, 2007) and  was 
“borrowed” from a prior usage by the US Food and Drug Agency (USFDA) where it was 
used pertaining to medical devices (Miller, 1999, 1042). 
Even  GMO  proponents  accept  that  “Substantial  equivalence  is  not  intended  to  be  a 
scientific  formulation;  it  is  a  conceptual  tool  for  food  producers  and  government 
regulators” (Miller, 1999, 1043). And there’s the rub - there is no scientific definition of 
“substantial equivalence”, no scientific test of  proof  of  concept, and nor is there likely to 
be, since this is a  ‘spinmeister’ term. And yet this is the  cornerstone on which rests the 
presumption of  safety of  GMOs. Absence of  evidence is taken to be evidence of  absence. 
History suggests that this is a  fraught presumption. By way of  contrast, the patenting of 
GMOs  depends  on  the  antithesis  of  assumed  ‘sameness’.  Patenting  rests  on  proven, 
scrutinised, challengeable and robust tests of difference and novelty. Lightfoot et al. (2000, 
1)  report  that  transgenic  plants  exhibit  “unexpected  changes  [that]  challenge  the  usual 
assumptions  of  GMO  equivalence  and  suggest  genomic,  proteomic  and  metanomic 
characterization of transgenics is advisable”.
GMO Milk and Contested Labelling
Pesticide  company  Monsanto  markets  the  genetically  engineered  hormone  rBST 
(recombinant Bovine  Somatotropin;  also  known  as:  rbST;  rBGH, recombinant  Bovine 
Growth Hormone; and the brand name Prosilac) to dairy farmers who inject it into their 
cows  to  increase  milk  production.  This  product  is  not  approved  for  use  in  many 
jurisdictions,  including  Europe,  Australia,  New  Zealand,  Canada  and  Japan.  Even 
Monsanto accepts that rBST leads to mastitis (inflammation and pus in the udder) and other 
“cow health problems”, however, it maintains that “these problems did not occur at rates 
that  would  prohibit  the  use  of  Prosilac”  (Monsanto,  2007). A  European  Union  study 
identified an extensive list of health concerns of rBST use (European Commission, 1999). 
The US Dairy Export Council however entertain no doubt. In their background document 
they ask “is milk from cows treated with rBST safe?” and answer “Absolutely” (USDEC, 
2006). Meanwhile, Monsanto’s website raises, and answers, the question: “Is the milk from 
cows treated with  rbST any  different from milk  from untreated cows? No” (Monsanto, 
2007). Injecting cows with genetically modified hormones to boost their milk production 
remains a contested practice, banned in many countries.
It is the  claimed equivalence that has kept consumers of  US dairy products in the dark, 
shielded rBST dairy farmers from having to declare that their  milk production is GMO-
enhanced, and has inhibited non-GMO producers from declaring their milk as non-GMO, 
non rBST, or not hormone  enhanced. This is a battle that has simmered, and sometimes 
raged,  for  a  decade  in  the  US. Finally  there  is  a  modest  victory  for  consumers:  the 
Pennsylvania Department of Agriculture (PDA) requires all labels used on milk products to 
be approved in advance by the department. The  standard issued in October 2007 (PDA, 
2007)  signalled  to  producers  that  any milk  labels  claiming  rBST-free  status  would  be 
rejected. This  advice  was  rescinded  in  January  2008  with  new,  specific,  department-
approved textual constructions allowed, and ensuring that any “no rBST” style claim was 
paired with a PDA-prescribed disclaimer (PDA, 2008).
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No labeling may contain references such as ‘No Hormones’, ‘Hormone Free’, ‘Free 
of  Hormones’,  ‘No  BST’,  ‘Free  of  BST’,  ‘BST  Free’,’No  added  BST’,  or  any 
statement which indicates, implies or could be construed to mean that no natural 
bovine somatotropin (BST) or synthetic bovine somatotropin (rBST) are contained in 
or added to the product (PDA, 2008, 3).
Difference claims are prohibited:
  In no instance shall any label state or imply that milk from cows not treated with
recombinant bovine somatotropin (rBST, rbST, RBST or rbst) differs in composition 
from  milk  or  products  made  with  milk  from  treated  cows, or  that  rBST  is  not 
contained in or added to the product. If a product is represented as, or intended to 
be represented to consumers as, containing or produced from milk from cows not 
treated with rBST any labeling information must convey only a difference in farming 
practices or dairy herd management methods (PDA, 2008, 3).
The PDA-approved labelling text for non-GMO dairy farmers is specified as follows:
  ‘From cows not treated with rBST. No significant difference has been shown
between milk derived from rBST-treated and non-rBST-treated cows’ or a substantial 
equivalent. Hereinafter, the first sentence shall be referred to as the ‘Claim’, and the 
second sentence shall be referred to as the ‘Disclaimer’ (PDA, 2008, 4).
It is onto the non-GMO dairy farmer alone, that the costs of compliance fall. These costs 
include label preparation and approval, proving non-usage of  GMOs, and of  creating and 
maintaining an audit trail.
In nearby Ohio a similar consumer versus corporatist pantomime is playing out. This time 
with the Ohio Department of  Agriculture (ODA)  calling the shots, and again serving the 
GMO industry. The ODA prescribed text allowed to non-GMO dairy farmers is “from cows 
not supplemented with rbST” and this is to be conjoined with the mandatory disclaimer “no 
significant difference has been shown between milk derived from rbST-supplemented and 
non-rbST supplemented cows” (Curet, 2008). These are “emergency rules”: they apply for 
90 days, and are proposed as permanent. Once again, the onus is on the non-GMO dairy 
farmers  to  document  and  prove  their  claims.  GMO  dairy  farmers  face  no  such 
governmental requirements, including no disclosure requirement, and thus an asymmetric 
regulatory impost is placed on the non-GMO farmer which opens up new opportunities for 
administrative demands and technocratic harassment.
Levidow et al. (2007)  argue, somewhat Eurocentrically, that from its 1990s adoption “as 
the basis for a harmonized science-based approach to risk assessment” (26) the concept of 
“substantial equivalence” has “been recast in at least three ways” (58). It is true that the 
GMO debate has evolved differently in the US and Europe, and with other jurisdictions 
usually adopting intermediate positions, yet the concept persists. Levidow et al. nominate 
their  three  recastings  as:  firstly  an  “implicit  redefinition”  by  the  appending  of  “extra 
phrases  in  official documents”; secondly, “it  has  been reinterpreted, as risk  assessment 
processes have … required more evidence of safety than before, especially in Europe”; and 
thirdly, “it has been demoted in the European Union regulatory procedures so that it can no 
longer be used to justify the claim that a risk assessment is unnecessary” (58).
Romeis et al. (2008)  have  proposed a  decision  tree  approach  to  GMO  risks  based on 
cascading tiers of risk assessment. However what remains is that the defects of the concept 
of “substantial equivalence” persist. Schauzu identified that: such decisions are a matter of 
“opinion”; that there is “no clear definition of  the term ‘substantial’”; that because genetic 
modification “is aimed at introducing new traits into organisms, the result will always be a 
different combination of  genes and proteins”; and that “there  is no general checklist that 
M/C Journal 11(2) May 2008                                      <journal.media-culture.org.au>                                                 
preprint version                                                       4                                                                                could be followed by those who are responsible for allowing a product to be placed on the 
market” (2).
Benchmark for Further Food Novelties?
The  discourse,  contestation,  and  debate  about  “substantial  equivalence”  have  largely 
focussed on the introduction of  GMOs into food production  processes. GM can best be 
regarded as the test case, and proof of concept, for establishing “substantial equivalence” as 
a benchmark for evaluating new  and forthcoming food technologies. This is of  concern, 
because  the  concept  of  “substantial  equivalence”  is  scientific  hokum,  and  yet  its 
persistence,  even  entrenchment,  within  regulatory  agencies  may  be  a  harbinger  of 
forthcoming  same-but-different  debates  for  nanotechnology  and  other  future 
bioengineering. 
The appeal of “substantial equivalence” has been a brake on the creation of GMO-specific 
regulations  and  on  rigorous  GMO  testing.  The  food  nanotechnology  industry  can  be 
expected to look to the precedent of the GMO debate to head off specific nano-regulations 
and nano-testing. As cloning becomes economically viable, then this may be another wave 
of  food innovation that muddies the regulatory waters with the confused - and ultimately 
self-contradictory - concept of “substantial equivalence”. 
Nanotechnology engineers particles in the size range 1 to 100 nanometres - a nanometre is 
one billionth of a metre. This is interesting for manufacturers because at this size chemicals 
behave  differently,  or  as  the  Australian  Office  of  Nanotechnology  expresses  it,  “new 
functionalities  are  obtained”  (AON,  2007).  Globally,  government  expenditure  on 
nanotechnology research reached US$4.6 billion in 2006 (Roco, 2007, 3.12). While there 
are now many patents (ETC Group, 2004; Roco, 2007), regulation specific to nanoparticles 
is lacking  (Bowman  and  Hodge, 2007; Miller  and Senjen, 2008). The  USFDA  (2008) 
advises  that  nano-manufacturers  “must  show  a  reasonable  assurance  of  safety  …  or 
substantial equivalence”.
A recent inventory of nano-products already on the market identified 580 products. Of these 
11.4% were categorised as “Food and Beverage” (WWICS, 2007). This is at a time when 
public  confidence  in  regulatory  bodies  is  declining  (HRA,  2007).  In  an  Australian 
consumer survey on nanotechnology, 65% of  respondents indicated they were concerned 
about “unknown and long term side effects”, and 71% agreed that it is important “to know 
if products are made with nanotechnology” (MARS, 2007, 22). 
Cloned animals are currently more expensive to produce than traditional animal progeny. In 
the course of  678 pages, the USFDA (2006) “Animal Cloning: A Draft Risk Assessment” 
has not a single mention of  “substantial equivalence”. However the Federation of Animal 
Science  Societies  (FASS)  in  its  single  page  “Statement  in  support  of  USFDA’s  risk 
assessment conclusion that  food  from cloned  animals is  safe  for  human  consumption” 
states that “FASS endorses the use of this comparative evaluation process as the foundation 
of establishing substantial equivalence of  any food being evaluated. It must be emphasized 
that it is the food product itself  that should be the focus of the evaluation rather than the 
technology used to generate cloned animals” (FASS, 2008, 1). 
Contrary to the  FASS derogation of  the  importance  of  process  in food production, for 
consumers both the  process  and provenance  of  production is  an important and  integral 
aspect of  a food product’s value and identity. Some consumers will legitimately insist that 
their Kalamata olives are from Greece, or their balsamic vinegar is from Modena. It was the 
British public’s growing awareness that their sugar was being produced by slave labour that 
enabled the boycotting of the product, and ultimately the outlawing of slavery (Hochschild, 
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boycott produce  of  USA because  of, for  example, US foreign policy or  animal welfare 
concerns, they are distinguishing the food based on the narrative of the food, the production 
process and/or production context which are a part of  the identity of  the food. Consumers 
attribute  value  to  food based on production process and provenance information (Paull, 
2006). Products produced by slave labour, by child labour, by political prisoners, by means 
of  torture, theft, immoral, unethical  or  unsustainable  practices  are  different  from  their 
alternatives. The process of production is a part of the identity of a product and consumers 
are  increasingly  interested  in  food  narrative.  It  requires  vigilance  to  ensure  that  these 
narratives  are  delivered  with  the  product  to  the  consumer,  and  are  neither  lost  nor 
suppressed.
Throughout  the  GM debate, the  organic  sector has successfully  skirted the  “substantial 
equivalence”  debate  by  excluding  GMOs  from  the  certified  organic  food  production 
process. This GMO-exclusion from the organic food stream is the one reprieve available to 
consumers worldwide  who  are  keen to avoid GMOs in their  diet. The organic industry 
carries  the  expectation  of  providing  food  produced  without  artificial  pesticides  and 
fertilizers,  and  by  extension,  without  GMOs.  Most  recently,  the  Soil Association,  the 
leading  organic  certifier  in  the  UK, claims  to be  the  first  organisation in  the  world to 
exclude manufactured nonoparticles from their products (Soil Association, 2008). There has 
been the call that engineered nanoparticles be excluded from organic standards worldwide, 
given that there is no mandatory safety testing and no compulsory labelling in place (Paull 
& Lyons, in press). 
The twisted rhetoric of  oxymorons does not make the ideal foundation for policy. Setting 
food policy on the  shifting sands of  “substantial equivalence” seems foolhardy when we 
consider the potentially profound ramifications of globally mass marketing a dysfunctional 
food. There is a  2x2 matrix  of  terms -  “substantial equivalence”, substantial difference, 
insubstantial  equivalence,  insubstantial  difference  -  and  while  only  one  corner  of  this 
matrix is engaged for food policy, and while the elements remain matters of opinion rather 
than being testable by science, or by some other regime, then the public is the dupe, and 
potentially the victim. “Substantial equivalence” has served the GMO corporates well and 
the public poorly, and this asymmetry is slated to escalate if nano-food and clone-food are 
also folded into the “substantial equivalence” paradigm. Only in Orwellian Newspeak is 
war  peace,  or  is same  different. It  is time  to  jettison the  pseudo-scientific  doctrine  of 
“substantial  equivalence”,  as  a  convenient  oxymoron,  and  embrace  full  disclosure  of 
provenance, process and difference, so that consumers are not collateral in a continuing 
asymmetric knowledge war.
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